Welcome @AmoebaNature as a featured exhibitor at the BioSolutions Conference & Expo!

Amoéba is an innovative #greentech company providing the industry with disruptive & sustainable solutions for key resource treatment. Learn more at


📣 Communiqué de presse :
#Amoéba annonce l’annulation de l’émission de la 8° tranche optionnelle d’OCA et la signature d’un contrat avec Redbridge Debt and Treasury Advisory afin d’adapter sa stratégie financière aux enjeux de transformation industrielle

📣 Communiqué de presse :
#Amoéba confirme son éligibilité au dispositif PEA-PME. Les #actions AMOEBA peuvent donc être intégrées dans les portefeuilles PEA PME, dédiés aux #investissements dans les #PME et #ETI selon les critères réglementaires.

🎥 @Fabrice Plasson, PDG d’#Amoéba, revient sur cette année exceptionnelle dans une vidéo dédiée au #bilan 2022 et aux #perspectives 2023. AMM, nouvelle usine, stratégie, plan de financement, tant de sujets abordés sur la chaîne #YouTube d’#Amoéba :

US EPA about to approve Amoéba’s biocide for use in closed cooling systems

Amoéba informs that the US EPA has made a positive pre-decisional determination for the use of Amoéba’s biocide in closed cooling systems

Lyon (France), August 10th, 2022 – 17h45 – AMOÉBA (FR0011051598 – ALMIB), producer of a biological biocide capable of eliminating bacterial risk in water and human wounds, and of a biocontrol product for plant protection, still in development phase, informs that the United States Environmental Protection Agency (US EPA) has made a positive pre-decisional determination following its assessment of the application dossier for the use of Willaertia magna C2c Maky as a biocidal active ingredient in cooling systems. 

The US EPA has concluded that the amoeba Willaertia magna C2c Maky and the BIOMEBA products containing it can be authorized on the United States territory for a biocidal use in closed cooling systems, for the control of microbial slime (bioslime), microbially induced corrosion and general microbial flora in cooling towers waters. 

Based on the last administrative steps required by the US EPA to finalize the procedure, the issuance of the marketing authorization of the products is expected by the end of 2022 at the latest. 

This is historic news that has just been sent to us by the US EPA. Amoéba has been legitimized in its application for the use of a microorganism in the treatment of bacterial risk in water. We will now refine our analysis of the market potential for this type of closed systems. We hope that the pragmatism of North American regulatory agencies will one day inspire European agencies. This decision adds a very positive note to the worldwide interest already in place for our biocontrol application and will influence the company’s future development.”, says Fabrice Plasson, CEO of Amoéba.